# EDGAR Filing Document

**Accession Number:** 0002120637
**File Stem:** 0001829126-26-006949
**Filing Date:** 2026-6
**Character Count:** 8288
**Document Hash:** 4b4ce9636a8c7b77938751cbf15fa0e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-26-006949.hdr.sgml**: 20260626

**ACCESSION NUMBER**: 0001829126-26-006949

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260626

**DATE AS OF CHANGE**: 20260626

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Indaptus Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001857044
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863158720
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92776
- **FILM NUMBER:** 261131029

**BUSINESS ADDRESS:**
- **STREET 1:** 3 COLUMBUS CIRCLE
- **STREET 2:** 15TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** (646) 427-2727

**MAIL ADDRESS:**
- **STREET 1:** 3 COLUMBUS CIRCLE
- **STREET 2:** 15TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Intec Parent Inc.
- **DATE OF NAME CHANGE:** 20210414
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Yao Yun
- **CENTRAL INDEX KEY:** 0002120637

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 5 CURRAGHBEENA ROAD
- **CITY:** MOSMAN
- **NON US STATE TERRITORY:** NSW
- **PROVINCE COUNTRY:** C3
- **ZIP:** 2088

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Indaptus Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.01 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Yun Yao**<br>8404 / 70 Southbank Boulevard<br>Southbank VIC C3 3006<br>0426 454 615

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/24/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Yao Yun** | Name of reporting person<br>**Yao Yun** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**C3** | Citizenship or place of organization<br>**C3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**41991000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**41991000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**41991000.00** | Aggregate amount beneficially owned by each reporting person<br>**41991000.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**31.51%** | Percent of class represented by amount in Row (11)<br>**31.51%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Yun Yao beneficially owns 41,991,000 shares of the Issuer's Common Stock. Such shares were acquired pursuant to the Securities Purchase Agreement, dated as of March 19, 2026 (the "Purchase Agreement"), and were issued upon the conversion of the Issuer's Series AA and Series AAA Preferred Stock in connection with the closing of the transaction on March 23, 2026. All percentage calculations herein are based on 133,242,324 shares of Common Stock outstanding of the issuer as of June 24, 2026, based on information provided in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 24, 2026. Please also refer to the Schedule 13D filed by Yun Yao on behalf of Yun Yao, Sino Lion Ventures Limited, Chenhao Xu, Junyi Dai, Ting Yang and Lina Deng with the Securities and Exchange Commission on March 30, 2026 and all amendments to date.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.01 per share

**(b) Name of Issuer:**
Indaptus Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
c/o Indaptus Therapeutics, Inc., 3 Columbus Circle, 15th Floor, New York, NY, 10019

Explanatory Note. This Amendment No. 2 ("Amendment No. 2") to Schedule 13D relates to the common stock, par value $0.01 per share (the "Common Stock") of Indaptus Therapeutics Inc., a Delaware corporation (the "Issuer"), and amends and supplements the initial statement on Schedule 13D originally filed by Yun Yao ("Reporting Person") on behalf of Yun Yao, Sino Lion Ventures Limited, Chenhao Xu, Junyi Dai, Ting Yang, and Lina Deng with the Securities and Exchange Commission ("SEC") on March 30, 2026, as amended by Amendment No. 1 filed on April 29, 2026 to report the disbandment of such group (collectively, the "Initial Schedule 13D", and as amended and supplemented by this Amendment No. 2, the "Schedule 13D").  Capitalized terms used but not defined in this Amendment No. 2 shall have the same meanings ascribed to them in the Initial Schedule 13D.

**Item 4. Purpose of Transaction**

The information set forth in Item 4 in the Initial Schedule 13D is incorporated herein by reference.

This Amendment No. 2 is being filed to report a decrease of more than 1% in the percentage of the outstanding Common Stock beneficially owned by the Reporting Person, resulting solely from the increase in the number of shares of Common Stock issued and outstanding upon the closing of the Issuer's private placement on June 17, 2026. The Reporting Person did not acquire or dispose of any shares of Common Stock in connection therewith.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information contained on the cover pages to this Schedule 13D is incorporated herein by reference. As of the date hereof, there are 133,242,324 shares of Common Stock outstanding as of June 24, 2026, as calculated based on the Issuer's Form 8-K filed with the SEC on June 24, 2026.

**(b)**
The following table sets forth the number of Common Stock as to which the Reporting Person has (i) the sole power to vote or direct the vote, (ii) shared power to vote or to direct the vote, (iii) sole power to dispose or to direct the disposition, or (iv) shared power to dispose or to direct disposition:

Reporting Person    Sole Voting Power   Shared Voting Power   Sole Dispositive Power   Shared Dispositive Power
Yun Yao                        41,991,000.00                      0                            41,991,000.00                               0

**(c)**
The Reporting Person have not effected any transaction in the shares of Common Stock during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in Item 6 in the Initial Schedule 13D is incorporated herein by reference. The information set forth in Item 3 and Item 4 above is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Yao Yun

**Signature:** /s/ Yun Yao

**Name/Title:** Yun Yao

**Date:** 06/26/2026